Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Enzymatica AB (publ) (ENZY.ST)
SEK2.32
+0.03 (+1.31%)
SE STO Healthcare Drug Manufacturers - Specialty & Generic
Address
Ideon Science Park 223 70
Lund, SE
Lund, SE
CEO
Sana Alajmovic
Website
enzymatica.se
IPO
2011-06-14
ISIN SE0003943620
Description
Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK2.32
+0.03 (+1.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
91.7K
Beta
-0.38
Float Shares
237.21M
Free Float %
97.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.74% | +13.75% | +7.48% | +39.29% | +41.45% | +42.19% | -9.00% | +5.81% | -73.90% | +24.66% | -52.44% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.32
Ratings Trend (MoM)
| Rating | 2025-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
22.65
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+18.3% ★ Q1'26: -6.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+25.0% ★ Q1'26: +25.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-90.4% Q1'26: -59.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-96.9% Q1'26: -117.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-56.7% Q1'26: -63.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+25.9% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.02× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
27.91M
est: 27.95M (-0.1%)
|
36.48M
est: 45.68M (-20.1%)
|
59.45M
est: 56.92M (+4.4%)
|
52.56M
est: 48.87M (+7.5%)
|
61.31M
est: 63.97M (-4.2%)
|
111.25M
est: 112.30M (-0.9%)
|
57.24M
est: 65.53M (-12.6%)
|
48.95M
est: 58.50M (-16.3%)
|
50.90M
est: 44.95M (+13.2%)
|
45.58M
est: 50.00M (-8.9%)
|
53.90M
est: 78.00M (-30.9%)
|
109.00M
105.86M – 112.14M
+39.7% YoY
|
| EBITDA |
-40.39M
est: -19.69M (-105.1%)
|
-42.61M
est: -32.18M (-32.4%)
|
-24.98M
est: -40.09M (+37.7%)
|
-33.58M
est: -34.42M (+2.5%)
|
-34.51M
est: -45.06M (+23.4%)
|
-5.23M
est: -79.10M (+93.4%)
|
-38.19M
est: -46.16M (+17.3%)
|
-59.97M
est: -41.21M (-45.5%)
|
-41.12M
est: -39.95M (-2.9%)
|
-49.23M
est: -44.43M (-10.8%)
|
-52.21M
est: -69.32M (+24.7%)
|
-96.87M
-99.66M – -94.08M
-39.7% YoY
|
| EBIT |
-40.80M
est: -21.40M (-90.7%)
|
-45.71M
est: -34.98M (-30.7%)
|
-30.33M
est: -43.58M (+30.4%)
|
-40.80M
est: -37.42M (-9.0%)
|
-41.59M
est: -48.98M (+15.1%)
|
-12.26M
est: -85.99M (+85.7%)
|
-44.81M
est: -50.18M (+10.7%)
|
-67.75M
est: -44.80M (-51.2%)
|
-47.63M
est: -42.14M (-13.0%)
|
-51.43M
est: -46.87M (-9.7%)
|
-52.21M
est: -73.12M (+28.6%)
|
-102.18M
-105.12M – -99.24M
-39.7% YoY
|
| Net Income |
-40.83M
est: -257.92M (+84.2%)
|
-45.01M
est: -63.77M (+29.4%)
|
-31.45M
est: -64.92M (+51.6%)
|
-42.58M
est: -83.60M (+49.1%)
|
-40.98M
est: -52.41M (+21.8%)
|
-13.22M
est: -10.49M (-26.0%)
|
-45.39M
est: -51.41M (+11.7%)
|
-68.66M
est: -57.03M (-20.4%)
|
-49.73M
est: -81.18M (+38.7%)
|
-53.18M
est: -72.82M (+27.0%)
|
-51.89M
est: -72.82M (+28.7%)
|
-72.82M
-72.82M – -72.82M
+0.0% YoY
|
| SGA |
52.11M
est: 32.71M (+59.3%)
|
57.32M
est: 53.45M (+7.2%)
|
56.62M
est: 66.60M (-15.0%)
|
57.80M
est: 57.19M (+1.1%)
|
59.14M
est: 74.85M (-21.0%)
|
66.52M
est: 131.41M (-49.4%)
|
55.42M
est: 76.68M (-27.7%)
|
71.50M
est: 68.46M (+4.4%)
|
67.79M
est: 58.85M (+15.2%)
|
68.02M
est: 65.46M (+3.9%)
|
69.67M
est: 102.11M (-31.8%)
|
142.69M
138.58M – 146.80M
+39.7% YoY
|
| EPS |
-1.44
est: -1.34 (-7.6%)
|
-0.49
est: -0.33 (-48.1%)
|
-0.35
est: -0.34 (-3.9%)
|
-0.45
est: -0.43 (-3.7%)
|
-0.29
est: -0.27 (-6.7%)
|
-0.09
est: -0.05 (-69.9%)
|
-0.31
est: -0.27 (-16.2%)
|
-0.41
est: -0.30 (-38.6%)
|
-0.28
est: -0.33 (+16.3%)
|
-0.28
est: -0.30 (+6.7%)
|
-0.21
est: -0.30 (+30.0%)
|
-0.30
-0.30 – -0.30
+0.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-26.79M
OE per share TTM
-0.11
Owner's Yield
-4.04%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
20.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-2.49M
Shares Outstanding
242.74M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sana Alajmovic | Chief Executive Officer | 5M | female |
| Anja Tragardh | Communications Manager | — | female |
| Anna Soderlund | Senior Director of Marketing & Sales | — | female |
| Holger Lembrer | Chief Financial Officer | — | male |
| Kristina Rylander | Acting Chief Financial Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ENZY.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
